Market Research Future (MRFR) suggests that the erythropoietin pharmaceutical market could achieve a decent CAGR of 9.5% during 2020-2027 (analysis period). Erythropoietin drugs or hematopoietin can be described as glycoprotein hormones that suppress excessive RBC production. Therefore, these drugs find wide application in the treatment of various diseases such as chronic kidney disease, cancer, anemia, and AIDS.
Get Sample Report : https://www.marketresearchfuture.com/sample_request/1360
3SBio, Amgen (US), Kyowa Hakko Kirin, Intus Pharmaceuticals (India), Teva Pharmaceuticals Industries (Israel), Johnson & Johnson (US), Encure Pharmaceuticals (India), LG Life Sciences (Korea), Dahua Pharmaceuticals (China), Biocon (India), Boehringer Ingelheim (USA), BIOSIDUS (Argentina), Hospira (USA), Hoffmann-La Roche (Switzerland), Celltrion (Korea) , MRFR Top contenders for industries featured in the report.
Encouraged by the surge in USFDA approvals, companies are striving to develop and bring new drugs to market. These companies are also focused on working on strategies such as partnerships, collaborations and acquisitions to further improve their market rankings.
Types, applications, and end-users are the major segments that have been considered in the MRFR study of Erythropoietin Pharmaceutical Industry.
- The types of erythropoietin drugs available on the global market include first generation formulations, biosimilars, and second generation formulations.
- The main uses of erythropoietin are HIV, renal disease, oncology, etc. The renal disease segment is the highest profitable in the global market given the surging burden of end-stage renal disease worldwide and the growing need for dialysis.
- In terms of end-users , the major segments could be Research Institutes, Regenerative Medicine Centers, Hospitals & Clinics.
Main boosters and challenges
The U.S. Department of Health and Human Services’ National Heart, Lung, and Blood Institute reveals that anemia affects more than 4 million individuals each year, and that number is expected to double in the next few years. This has led to an urgent need for erythropoietin stimulants and a high potential for the global market to witness significant growth in the coming years.
The emergence of new drugs and cheaper, more effective biosimilar formulations with better efficacy and cost-effectiveness could provide many lucrative opportunities for major manufacturers in the coming years. For example, the development of several biosimilars is touted as gaining momentum in Europe in the coming years, and their use is also expected to increase. Biosimilars offer a variety of benefits, including faster time to approval, better therapeutic efficacy, and greater cost efficiency.
In recent years, nemic conditions have gained traction, fueled by chemotherapy, antiretroviral therapy (ART), and renal disease treatment, and replaced by a strong demand for erythropoietin drugs. As a result, the escalation of chemotherapy treatment cycles and the surge in end-stage renal disease cases were favorable to the global industry. Apart from this, new commercialization trends regarding erythropoietin biosimilars, supportive reimbursement, flexible government regulation, and soaring levels of awareness about the benefits of EPO therapeutics are likely to expand the market size in the ensuing years. There is a nature.
The erythropoietin pharmaceutical industry is regionally segregated into Asia Pacific/Asia Pacific, Europe, Middle East/Middle East and Africa, and North America.
Given the surging burden of chronic diseases such as CKD, HIV and cancer, North America secures the lead in the global market and has the highest sales of erythropoietin drugs. The Centers for Disease Control and Prevention (CDC) has confirmed that there are more than 2.2 million HIV-positive people in the United States, with 45,513 documented diagnosed cases in 2015. These statistics reflect the growing need for effective EPO drugs in the region. In addition, as biologics patents near expiry, many new companies are entering the regional market and adopting several strategic initiatives to enhance revenue.
Asia Pacific has great growth potential and has emerged as a strong market for erythropoietin drugs over the years. Most global companies are focused on setting up operations in this region due to the rapid emergence of biosimilars and the high number of unmet medical needs. China and India are some of the top performers in the APAC market, largely buoyed by aggressive governments funding intensive research and development activities. Also, biosimilars in various countries in the region like India do not require Phase I and Phase II trials and only have Phase III evaluations required for at least 100 patients. As a result, most manufacturers in the region are able to launch biosimilar versions of erythropoietin at 30-40% lower cost than innovator products.
In Europe, rising R&D spending on biosimilars, a strong product pipeline and increasing joint ventures between manufacturers and hospitals for the deployment of EPO biosimilars are supporting business growth.
For example, in July 2021, Avalon GloboCare Corp., a company with a reputation for developing advanced cell-based technologies and therapeutics, announced that Avalon’s acquisition target, SenlangBio, is a human We have confirmed that we have started the first evaluation in Tyrosine kinase) CAR T-cell therapy for treating recurrent glioblastoma.
View Full Report : https://www.marketresearchfuture.com/reports/erythropoietin-drug-market-1360
Related reports :
Market Research Future (MRFR) provides insights into various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), Market Research & Consulting Services. It allows us to unravel the complexity.
Market Research Future (part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor, New York,
new york 10013